Investors Presentation

September 2015

An experienced leadership team

2

Jérôme Destoppeleir

Kurt Kelln

Philippe LutmanClaude Cohen-Bacrie

Jacques Souquet, PhD

Executive VP and COO

Executive VP at Océ (Canon Group)

Executive VP, CEO EMEA and Latin America,

Philips, Philips Medical Systems

CEO KMD, Kommunedata

Tom Egelund

Executive VP, Founder and Chief

Innovation Officer

Former CEO SuperSonic Imagine

Former CTO ATL & Philips Medical Systems

Past and Present Board Membership: SonoSite,

Median, X’Counter

Member of the French Academy of Technologies

Executive VP, Founder and CTO

Former lead of Ultrasound activities at

Philips Research

Holds 15+ Medical Imaging Patents

Board Member EyeTechCare

Executive VP and CFO

Former VP finance at Homair vacances

Former VP finance at PGA motors

Former VP finance at Delta Plus and ONET

20+ years listed companies experience

Executive VP of Sales and Marketing

Former VP of Sales and Marketing for Ultrasound

and WHC, Philips Healthcare

20+ years sales and marketing leadership

experience

Executive VP, Chief Customer Fulfilment

Officer

COO at Acteon (Dental and Medical Imaging)

Board Member Vodasystems

Former CTO at Sybase365

Former Marketing Director at Gemalto

Supersonic Imagine: better cancer diagnosis / screening and vascular pathologies detection

Provide unique clinical solutions to address patient, clinicians / customers and payers needs

Capture growth from emerging geographies and dedicated clinical specialties

Address specialized markets to maximize our platform’s technological value

Strategic vision

Become a major player in premium and compact innovative ultrasound

in 5 years in meaningful geographic markets

4

Concrete opportunities in a huge estimated $5.8bn market for a well reimbursed modality

New generation ultrasound platform for malignancy diagnosis with major clinical improvement

First significant innovation in ultrasound in 15+ years

Strong incentive for all stakeholders (patients, physicians, hospitals, healthcare systems)

1,150+ machines in 50+ countries

SuperSonic Imagine: a dedicated 100% ultrasound player

5

General Radiology, Hepatology

A rapid development on the ultrasound market

SuperSonic Imagine: snapshot on a successful French MedTech story

*Including own and shared patents

6

MUSCULO SKELETAL

Strong performance

in Israel

9 systems installed in

the Paris Radiology

Institute

(IRP)

Winner of the “Breakthrough

Technology Designation” award

Appointment of Tom

Egelund as Director of

Operations

Michael Brock

joins he

supervisory

board as Vice

Chairman

Clinical trial to

confirm the

benefits of its

technology on

dense breast

tissue

Exclusive

distribution

agreement with

Konica Minolta, Inc.

Collaboration to develop a

photo-acoustic and

ultrasound imaging device

Regulatory approval in 54

countries

BREAST

LIVER

THYROÏD

PROSTATE

CLINICAL INDICATIONS

REGULATORY / CORPORATE

2005 IPO 2014

2015

Japanese regulatory approval

Herman RequardtSupervisory Board’s

Independent Strategic Advisory

LIVER

Positive results for the clinical trial confirming

the technology’s medical benefits

1,150+ machines in 54 countries in 6 years and half years

Solid installed based of prestigious hospitals worldwide

28%45%

27%

EMEA

APAC (Asia-Pacific)

Installed base geographical breakdownat 6/30/2015

7

Installed base growth over 5 years

North America

Reference customers

No license required

Approved

64 209 352541

773+1,000

+1,150

2009 2010 2011 2012 2013 2014 H1 2015

Significant innovations in the medical ultrasound imaging industry

Patented software platform:Essential leverage in the design of innovations

9

Aixplorer, a generation ahead on the premium segment

MODE2D B-mode - 3D B-mode

Doppler: Color, PW ARFI, Static Elastography

Up to 32x multiline

Radiology - Cardiology – Vascular - OB/Gyn

POWER

APPLICATIONS

Ultrafast ShearWave Elastography

3D Elastography

256x multiline

RadiologyVascular

Specialty medicine

GLOBAL PERFORMANCE

Breakth

ro

ug

h t

ech

no

log

y

HARDWARENo significant innovation for 15 years

SOFTWARESignificative innovation

New real time imaging modes to surpass existing mode performances

New imaging techniques

Regular updates

Excellent image quality in B-mode

Overcoming imaging limitations of HW based systems

Hardware

Patented software: SonicSoftware™

Conventional Imaging

Ultrafast™ Imaging

capture of 20,000 images / second(c.200 times faster than conventional ultrasound)

Hardware processing 1 received signal per transmit beam

Multiple HW boards (~10~ 15)

Software processingGPU

All RF lines of the image

10

Supersonic ShearWave Elastography: the only real time implementation

Fibroscan

Liver

Single shot average measurement

Supersonic Imagine

Real timemeasurements over

the entire image

Breast, Liver, Thyroid, Prostate, Gyn, MSK

Siemens, Philips

Liver

Breast (WIP)

Single shot line measurement

MRI elastography

Offline image computation (30 minutes)

Liver

Prostate Liver

11

Mean velocity in a colour coded representation

Quantification of velocity in 1 given location

Improved colour imaging and quantification of flow velocity everywhere

Imaging

OR

Quantification

Breaking the compromise betweenflow imaging and flow quantification

How Ultrafast™ Doppler changes the rules of the game

High sensitivity and acquisition speed

high quality visualization of flows

significantly simplified and shorter doppler exams

Conventional Doppler Ultrafast Doppler

Imaging QuantificationAND

12

AND

AND

I Main terms of the offering

Strong clinical positioning on main applications in radiology

PROSTATE Effective biopsy guidance

VASCULAR Quantitative imaging of vascular function

BREAST Reduce the number of unnecessary biopsies

LIVEREnabling fibrosis assessment without

biopsies

Clinically-proven improvement of cancer diagnosis strategyand vascular function assessment

13

MUSCULO-SKELETAL

Real-time visualization of anatomical and

functional image of the muscle during the

effort

Clinical strategy: all clinical frameworks and applications

Prostate

Increased sensitivity (100%) for prostate

cancer screening (Barr et al.) Role of SWE in targeting of prostate biopsies to increase detection

Improved characterisation of prostate cancer nodules

(Correas et al.) SWE better than Colour Doppler and CEUS*

* CEUS = Imagerie de contraste ultrasonore

14

Breast

Improved diagnosis

better classification of lesions between BI-RADS 3 and BI-RADS 4

Allowing breast screening

focus on dense breast in Asian countries

Improving therapy monitoring

Tumour volume & monitor treatment

BI-RADS 3 BI-RADS 4

BI-RADS 4 BI-RADS 3

Musculo-Skeletal

Non invasive fibrosis assessment

SWE surpasses FibroScan on Hep B / Hep C patients

(Ferraioli)

Ultrasound all-in-one solution

(Fibrosis, Cirrhosis, HCC)

Liver

SWE Aixplorer depending of

metavir

FibroScan depending of metavir

Improved diagnosis

Sensitivity and accuracy of the color Doppler

Spatial resolution and contrast (image quality mode B)

Optimal ergonomics

H1 2015 main events

Changes within the Management and Supervisory Board

16

Supervisory BoardManagement Board

Jérôme DestoppeleirChief Financial Officer

Philippe LutmanChief Customer Fulfilment Officer

Tom EgelundManagement Board President

Brad Garrett

Gordon Waldron

Jacques SouquetChief Innovation Officer

Michael BrockSB Vice-President

Ex-CEO BK Medical

Bernard Daugeras

Auriga Partners Repr.

Bernard DoorenbosInterim President of the SB

Ex-MD of Axxicon Group, Neways

Electronics, Vilenzo International…

Hans Barella

SB Ex-President

Hermann RequardtIndependant Strategic Advisor

Ex-MD of Siemens Healthcare dép.

Corporate Technology

US distribution strategy evolution

17

Direct distributionDirect

distribution

Exclusive distribution partnership

10 employees (sales + apps)

+

3 employees max per services

PROSTATE

BREAST LIVER

MSKPROSTATE

BREAST

LIVER

MSK

2014Sept. 2015

+

APAC (1/2): Japanese regulatory approval

18

In Japan, Aixplorer is commercialized by the Japanese market leader, Konica Minolta, via an exclusive distribution agreement signed in January 2015

Kazuyoshi Hata, Healthcare Business Unit President, Konica Minolta and Jacques Souquet, Chief Innovation Officer, SuperSonic Imagine at JSUM

Buoyant success Aixplorer presentation by Konica Minolta to the medical community

during the annual scientific meeting of the Japan Society of Ultrasonics in Medicine

(JSUM), Tokyo, May 22 – 24, 2015.

Strong growth dynamic in China

APAC (2/2): Strong commercial ramp up in China

Regional organization with dedicated sales managers by area

Creation of a society dedicated to tenders (WFOE)

19 distributors

19

Well structured organization

+124% for H1 2015

28% of H1 2015 sales

(vs. 13% for H1 2014)

Multi distributor covered province

Current office locations

May consider author solo Distributor per province

Provinces covered by whole distributor

2014 expected office locations

Distribution network in China

Representative office in Beijing

H1 2015 finances

7,400 7,440

719 811

H1 2014 H1 2015

Products Services

A growth primarily driven by Asia

Sales increase during H1 2015

21

(‘000 euros)

8,251

H1 2015 sales changes by business activities

+13%

+1% H1 2015 sales distribution by business activities

90%

10%

Products Services

8,119 +2%

H1 2014/2015 sales geographical distribution

Asia

34%

Americas

26%

EMEA

40%Asia

43%

Americas

20%

EMEA

37%

H1 2014 H1 2015

Financial results for H1 2015

22

(1) Gross margin on sales = Sales – Cost of sales(2) Gross margin as a % of sales = Gross margin on sales / Sales

Thousands of euros H1 2015 H1 2014 Changes (%)

Sales 8,251 8,119 +1.6%

Other revenue 491 1,097 -55.2%

Total revenue 8,742 9,216 -5.1%

Cost of Sales -4,908 -5,039 -2.6%

Gross Margin 3,834 4,177 -8.2%

Gross Margin on Sales1 3,343 3,080 +8.5%

Gross margin as a % of sales 2 40.5% 37.9% +2.6 pts

Current Operating Result -7,041 -4,399 -60.0%

Operating Result -7,041 -4,718 -49.2%

Financial Result 151 -208 +172.6%

Net profit/(Lost) -6,951 -4,973 -39.8%

Gross Margin on Sales H1 2015: +2.6 points at 40,5% (vs. 37.9% in H1 2014)

Efforts to improve margins through production relocation in Malaysia + positive currency effects

Operating Result: -60% to €-7.0m (vs. €-4.4m)

Significant increase in general and administrative costs (x2 in 1 year). The company has not record any operating costs

Net profit at €-7.0m (vs. €-5.0m as of June 30, 2014)

Thousands of euros 6/30/2015 6/30/2014

Intangible assets 8,522 7,464

Tangible assets 1,438 1,279

Other non current assets 2,387 2,509

Total Non current assets 12,347 11,251

Inventories 6,424 4,234

Trade Receivables 7,479 8,417

Other current assets 5,845 5,809

Cash & cash equivalents 30,987 42,204

Total current assets 50,735 60,664

Total Assets 63,082 71,915

Shareholders equity 44,278 51,062

Financial liabilities (LT) 5,600 5,562

Other Non current liabilities 1,072 1,080

Total Non current liabilities 6,672 6,643

Financial liabilities (short term) 3,021 3,021

Account payable 4,165 4,525

Other current liabilities 4,947 6,664

Total current liabilities 12,133 14,210

Total liabilities 63,082 71,915

Balance Sheet as of June 30, 2015

23

Cash: €31.0m

€30.9m available

€0.1m as Other non current assets

Change in trade receivables (excluding other income): +14% against +17% for sales

Balance of outstanding receivables not impaired: €798 million ( against €957 million at the end of 2013 )

Of which €693 million collected in January and February 2015

Capital increase of €39.3m (IPO & results for the period)

Comments

1 Estimate in the US

Structured sales organization’s summary

Offensive sales approach to catch worldwide growth:all clinical applications everywhere

Specific approach through a

representative office in Beijing

Recruit and manage a network of agents and

dealers

Exclusive distribution

agreement with Konica Minolta ,

Inc. in Japan

Representative OfficeDirect distribution Indirect distribution

24

Distributors covering EMEA , Latin America and Asia

(excluding China)

Strong potential for developing medical devices or equipment

renewal

I Main terms of the offering

Strategy and Outlook

A clear development strategy

26

Set up a real differentiation strategy compared to the majors

Become a reference in some specialized indications with strong commercial potential…

…and capitalize on this differentiation in order to better enter the General Imaging segment

LIVER PROSTATEBREAST

Materialize specialized indications’ technologic advantage into competitive advantage by creating leading positions

Recover a good dynamic in the US

Continuing growth in Asia

Geographical commercial expansion

A newly defined distribution strategy

27

Continue the reinforcement of direct sales forces

Validate the last years success by adjusting our product line

and prices

Priority Regions

China

• 30 + 2 dedicated to Services• 19 distributors

France

• 7 + 8 dedicated to Services• 3 distributors

Continue to invest in the actual structure

+

Clinical trials in progress(12 sites - breast / 9 sites - liver)

North America

• 11 + 3 dedicated to Services2 distributors

High growth potential in premium / high-end

Short term action plan

28

Increase investments on 1 or 2 special indications

Focus on short term milestones taking advantage of the existing Aixplorer platform

Take immediate measures in order to boost the global growth:

• Specific actions regarding the price positioning in Europe and the US.

• Dedicate important efforts to our penetration strategy on breast cancer and hepatology markets in France and in the US

• Develop the Urology indication in Germany

• Increase the number of sales representatives in the US from 4 to 7

PLATEFORM B

Development of next generation modular platform

Platform B : reinforce strategic advantages of Aixplorer

Mobile compact

Shared service

Premium / High end

29

Tablet

Docking station Cart

Shell for tablet

Docking station for tablet

Complete system

Electronic acquisition card

Computing power

Power

Engine

Mechanical

enclosure

Probes

1

2

3

At the cutting edge of innovation by addressing new clinical applications

Source: In Medica (2013) 30

Complete clinical value on current application and create promising perspectives by leveraging the technology

Premium / high-end

Mid-range(shared service)

Specialty(Compact)

Breast / Thyroid

Liver /Abdomen

Prostate / Gyn.

Pediatric

+ Trans Cranial Doppler

+ Obstetrics

+ Urology

+ Screening and Therapy

+ Urology

+ Hepato/Gastro

Wider penetration of care centers (Compact)

Vascular+ Cardiology

Radiology and shared service

2017-2022 2013-2016

2 connectors

2012

Hepatology

Vascular labs

4 connectors Product line

+ Musculoskeletal

Capture c.7% market share of the total ultrasound industry in 10 years

Achieve a gross margin of c.60% in the mid term

Achieve an EBITDA margin of c.20% in the mid term

Reach EBITDA break-even within 4 years

Financial objectives

31

I Main terms of the offering

32

SuperSonic Imagine in the Market

* Including Management and employees

Market Cap: €60m (09/11/2015)

Analyst Coverage

Guillaume CUVILLIER

Romain ZANA

Patrick JOUSSEAUME

Sébastien MALAFOSSE

SuperSonic ImagineJerome Destoppeleir

Chief Financial Officer+33 4 88 19 68 55

gordon.waldron@supersonicimagine.com

NewCapInvestor Relations & Financial

CommunicationFlorent Alba / Pierre Laurent

+33 1 44 71 94 94supersonicimagine@newcap.fr

Shareholding Structure as of July 31, 2014 Financial Calendar

Contacts

Event Date

2015 First-Quarter Sales April 21, 2015

Annual General Meeting May 29, 2015

2015 First-Half Sales July 21, 2015

2015 First-Half Results September 14, 2015

2015 Third-Quarter Sales October 20, 2015

2015 Full-Year Sales January 19, 2016

Others

40%

EDRIP

12%

Auriga Partners

10%

Omnes Capital

11%

Caisse Des

Dépôts

10%

Bpifrance

Investissements

9%

NBGI Private

Equity

8%